1
|
Oliel S, Bierbrier R, D'Aguanno K, Esfahani K, Pehr K. Differences in Management Between Dermatologists and Oncologists for Acneiform Eruptions in Patients on Monoclonal Antibody Epidermal Growth Factor Receptor Inhibitors. J Cutan Med Surg 2024; 28:79-81. [PMID: 38156654 DOI: 10.1177/12034754231217248] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/03/2024]
Affiliation(s)
- Sarah Oliel
- Faculty of Medicine, McGill University, Montréal, QC, Canada
| | - Rachel Bierbrier
- Division of Dermatology, McGill University, Montréal, QC, Canada
| | - Kathleen D'Aguanno
- Division of Dermatology, Université de Sherbrooke, Sherbrooke, QC, Canada
| | - Khashayar Esfahani
- St. Mary's Hospital, McGill University, Montréal, QC, Canada
- Sir Mortimer B. Davis Jewish General Hospital, McGill University, Montréal, QC, Canada
- Division of Medical Oncology, Sir Mortimer B. Davis Jewish General Hospital, Montréal, QC, Canada
| | - Kevin Pehr
- Faculty of Medicine, McGill University, Montréal, QC, Canada
- Sir Mortimer B. Davis Jewish General Hospital, McGill University, Montréal, QC, Canada
- Lady Davis Institute for Medical Research, Montréal, QC, Canada
| |
Collapse
|
2
|
Bierbrier R, D'Aguanno K, Kasymjanova G, Dell'Aniello S, Agulnik J, Pehr K. Prognostic factors for the development of acneiform eruptions in patients on epidermal growth factor receptor inhibitors. J Am Acad Dermatol 2023; 88:869-870. [PMID: 36228936 DOI: 10.1016/j.jaad.2022.10.005] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/11/2022] [Revised: 09/19/2022] [Accepted: 10/04/2022] [Indexed: 11/07/2022]
Affiliation(s)
- Rachel Bierbrier
- Division of Dermatology, McGill University, Montréal, Québec, Canada
| | | | - Goulnar Kasymjanova
- Division of Pulmonary Diseases, Sir Mortimer B. Davis Jewish General Hospital, McGill University, Montréal, Québec, Canada
| | - Sohie Dell'Aniello
- Center for Clinical Epidemiology, Lady Davis Institute, Sir Mortimer B. Davis Jewish General Hospital, Montréal, Québec, Canada
| | - Jason Agulnik
- Division of Pulmonary Diseases, Sir Mortimer B. Davis Jewish General Hospital, McGill University, Montréal, Québec, Canada
| | - Kevin Pehr
- Division of Dermatology, McGill University, Montréal, Québec, Canada; Lady Davis Institute, Sir Mortimer B. Davis Jewish General Hospital, McGill University, Montréal, Québec, Canada.
| |
Collapse
|
3
|
D'Aguanno K, Meloche L, Vera C, Jasso-Olivares JC. Modes of Transmission and Clinical Manifestations of Monkeypox Virus. J Cutan Med Surg 2022; 26:534-535. [PMID: 35943038 DOI: 10.1177/12034754221116122] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
Affiliation(s)
| | - Laurence Meloche
- 12369 Faculty of Medicine, Université Laval, Quebec City, QC, Canada
| | - Caridad Vera
- 113594 Division of Dermatology, CISSS de Lanaudière, Saint-Charles-Borromée, QC, Canada.,12369 Department of Dermatology, Université Laval, Quebec City, QC, Canada
| | - Julio C Jasso-Olivares
- 113594 Division of Dermatology, CISSS de Lanaudière, Saint-Charles-Borromée, QC, Canada.,12369 Department of Dermatology, Université Laval, Quebec City, QC, Canada
| |
Collapse
|
4
|
D'Aguanno K, Jack C, Muntyanu A, Netchiporouk E. LB915 Occupational and environmental triggers of atopic dermatitis. J Invest Dermatol 2022. [DOI: 10.1016/j.jid.2022.05.933] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/17/2022]
|
5
|
D'Aguanno K, Gabrielli S, Ouchene L, Muntyanu A, Ben-Shoshan M, Zhang X, Iannattone L, Netchiporouk E. Omalizumab for the Treatment of Bullous Pemphigoid: A Systematic Review of Efficacy and Safety. J Cutan Med Surg 2022; 26:404-413. [PMID: 35379011 DOI: 10.1177/12034754221089267] [Citation(s) in RCA: 11] [Impact Index Per Article: 5.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Bullous pemphigoid (BP) is an autoimmune blistering skin disease. Current treatment strategies are limited by their efficacy and/or side effect profile and the need for safer and effective alternatives is undeniable. We aimed to conduct a systematic review focusing on the efficacy and safety of omalizumab in BP patients. Embase, PubMed, Cochrane, and clinicaltrials.gov were searched for English and French articles published from inception to July 1, 2021, using search terms "omalizumab" OR "Xolair" OR "IGE025" OR "olizumab" AND "bullous pemphigoid." Screening and data extraction was performed by two raters independently. The primary outcome was complete response (CR), and secondary outcomes were partial response (PR), flare-ups, adverse events/vital status. In total, 22 articles were included, with a total of 56 patients. All patients had a refractory BP with mean disease duration of 13.5 ± 20.2 months (Standard Deviation (SD)) and failed 3.1 ± 1.6 therapies and many remained corticosteroids dependent. Overall, 87.5% of patients responded to treatment (55.4% CR and 32.1% PR), 7.1% discontinued the protocol and only 5.4% were non responders. A third of patients were able to discontinue all other therapies and most others were able to discontinue or taper systemic corticosteroids to <10 mg daily. Flare-ups occurred in 57.7% of patients upon discontinuation of omalizumab and/or steroid tapering, most patients recaptured response thereafter. Omalizumab was well tolerated by most patients. Omalizumab appears to be a promising treatment for BP with a good response rate and safety profile. However, several limitations were identified in current literature, and highlight the need for randomized controlled trials of omalizumab in BP.
Collapse
Affiliation(s)
| | | | - Lydia Ouchene
- 54473 Division of Dermatology, Montreal General Hospital, McGill University Health Centre, QC, Canada
| | - Anastasiya Muntyanu
- 54473 Division of Dermatology, Montreal General Hospital, McGill University Health Centre, QC, Canada
| | - Moshe Ben-Shoshan
- Division of Allergy, Clinical Immunology and dermatology, Department of Pediatrics, Montreal Children's Hospital, McGill University Health Centre, Montreal, QC, Canada
| | - Xun Zhang
- Centre for Outcomes Research and Evaluation, Research Institute of McGill University Health Centre, Montreal, QC, Canada
| | - Lisa Iannattone
- 54473 Division of Dermatology, Montreal General Hospital, McGill University Health Centre, QC, Canada
| | - Elena Netchiporouk
- 54473 Division of Dermatology, Montreal General Hospital, McGill University Health Centre, QC, Canada
| |
Collapse
|
6
|
Ghazal S, Ridha Z, D'Aguanno K, Nassim D, Quaiattini A, Netchiporouk E, Poulin Y, Kalia S, Marcoux D, Piguet V, Jack C. Treatment Guidelines for Atopic Dermatitis Since the Approval of Dupilumab: A Systematic Review and Quality Appraisal Using AGREE-II. Front Med (Lausanne) 2022; 9:821871. [PMID: 35355606 PMCID: PMC8959491 DOI: 10.3389/fmed.2022.821871] [Citation(s) in RCA: 9] [Impact Index Per Article: 4.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/24/2021] [Accepted: 01/21/2022] [Indexed: 01/04/2023] Open
Abstract
Introduction Since its approval for adults with moderate-to-severe atopic dermatitis (AD) in 2017, dupilumab has been incorporated into clinical practice guidelines (CPGs). However, recommendations differ internationally, and the quality assessment of their development is unclear. Objective We aimed to systematically review and appraise the quality of CPGs for adult AD reported since 2017 and map the recommendations for dupilumab initiation relative to conventional systemic therapy (CST). Materials and Methods A literature search was conducted in June 2020 in MEDLINE, EMBASE, SCOPUS, and CINAHL. Twelve CPGs were retrieved. Methodological quality was assessed using the validated Appraisal of Guidelines for Research & Evaluation II tool (AGREE-II). Recommendations were extracted and compared. Results AGREE-II median scores per domain of the CPGs were (%, r = range): scope/purpose, 78% (50-96); stakeholder involvement, 54% (28-85); rigor of development, 39% (21-63); clarity of presentation, 85% (69-100); applicability, 27% (6-51); and editorial independence, 76% (42-100). Neither met the threshold of 70% quality criteria for rigor of development nor the applicability domains. Three CPGs met the criteria for recommendation without modification. CPGs' approach to dupilumab initiation was as follows: second line, preferred over CST and nbUVB (n = 1/12 CPG); second line, equivalent to CST or nbUVB (n = 3/12 CPGs); third line, after nbUVB or CST (n = 5/12 CPGs); and fourth line after nbUVB and CST (n = 2/12). No consensus was reached for n = 1/12 CPG. Conclusion and Relevance Dupilumab is now incorporated into CPGs for adult AD. These CPGs exhibited good quality in scope/purpose, clarity, and editorial independence domains. However, none met AGREE-II criteria for methodological rigor/applicability. Gaps were found in mechanisms for updates, facilitators/barriers, resource implications, and stakeholder involvement. Only n = 3/12 CPGs met quality criteria for recommendation without modifications. Of these, two favored a conservative sequential approach for the initiation of dupilumab relative to CST, while one did not reach consensus. Our findings highlight divergent recommendations AD treatment, underlining a need to incorporate quality criteria into future guideline development.
Collapse
Affiliation(s)
| | - Zainab Ridha
- Faculty of Medicine, Université Laval, Quebec City, QC, Canada
| | | | - David Nassim
- Faculty of Medicine, McGill University, Montreal, QC, Canada
| | - Andrea Quaiattini
- Schulich Library of Physical Sciences, Life Sciences, and Engineering, McGill University, Montreal, QC, Canada
| | - Elena Netchiporouk
- Division of Dermatology, McGill University Health Center, Montreal, QC, Canada.,Infectious Diseases and Immunity in Global Health, The Research Institute of the McGill University Health Center, Montreal, QC, Canada
| | - Yves Poulin
- Centre de Recherche Dermatologique du Québec Métropolitain, Quebec City, QC, Canada
| | - Sunil Kalia
- Department of Dermatology and Skin Science, Vancouver Coastal Health Research Institute, Vancouver, BC, Canada
| | - Danielle Marcoux
- Department of Pediatrics, Division of Dermatology, Sainte-Justine University Hospital Center, University of Montreal, Montreal, QC, Canada
| | - Vincent Piguet
- Division of Dermatology, Department of Medicine, University of Toronto, Toronto, ON, Canada.,Division of Dermatology, Women's College Hospital, Toronto, ON, Canada
| | - Carolyn Jack
- Faculty of Medicine, McGill University, Montreal, QC, Canada.,Division of Dermatology, McGill University Health Center, Montreal, QC, Canada.,Infectious Diseases and Immunity in Global Health, The Research Institute of the McGill University Health Center, Montreal, QC, Canada.,Divisions of Dermatology, St. Mary's Hospital, Montreal West Island Integrated University Health and Social Services Centre, Montreal, QC, Canada.,Jewish General Hospital, Montreal West-Central Integrated University Health and Social Services Centre, Montreal, QC, Canada
| |
Collapse
|
7
|
D'Aguanno K, Muntyanu A, Ouchene L, Litvinov IV, Netchiporouk E. In Preparation for Biosimilar "Switch" Policy: How to Mitigate the Nocebo Effect. J Cutan Med Surg 2021; 26:203-205. [PMID: 34649465 DOI: 10.1177/12034754211048674] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Affiliation(s)
| | - Anastasiya Muntyanu
- 507266 Division of Dermatology, McGill University Health Center, Montreal, QC, Canada
| | - Lydia Ouchene
- 507266 Division of Dermatology, McGill University Health Center, Montreal, QC, Canada
| | - Ivan V Litvinov
- 507266 Division of Dermatology, McGill University Health Center, Montreal, QC, Canada
| | - Elena Netchiporouk
- 507266 Division of Dermatology, McGill University Health Center, Montreal, QC, Canada
| |
Collapse
|